Clozapine in schizophrenia patients with recurrent catatonia: Report of two cases

Psychiatry and Clinical Neurosciences

Volumn 60, Issue 2, 2006, Pages 256-258

  Hung, Yi Yung ^a   Yang, Ping Suen ^a   Huang, Tiao Lai ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Catatonia; Clozapine; Diazepam; Lorazepam; Schizophrenia

Indexed keywords

BENZODIAZEPINE; CLOZAPINE; DIAZEPAM; HALOPERIDOL; LORAZEPAM; LOXAPINE; NEUROLEPTIC AGENT; RISPERIDONE;

ADULT; ARTICLE; CASE REPORT; CATATONIA; CATATONIC SCHIZOPHRENIA; CLINICAL FEATURE; DISEASE DURATION; DRUG EFFECT; ELECTROCONVULSIVE THERAPY; FEMALE; FOLLOW UP; HUMAN; MUTISM; RECURRENT DISEASE; STUPOR;

ADULT; ANTIPSYCHOTIC AGENTS; CATATONIA; CLOZAPINE; FEMALE; HUMANS; RECURRENCE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 33644960195     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2006.01495.x     Document Type: Article

References (24)

1. Steinman TI Yager HM Catatonia in uremia AnnInternMed 1978 89 74 75
2. Steinberg P Adrenal carcinoma and hypertension presenting with catatonic stupor AustNZJPsychiatry 1996 30 146 149
3. Woods SW Catatonia in a patient with subdural hematomas AmJPsychiatry 1980 137 983 984
4. Pfister HW Preac-Mursic V Wilske B et al. Catatonic syndrome in acute severe encephalitis due to Borrelia burgdorferi infection Neurology 1993 43 433 435
5. Gelenberg AJ Mandel MR Catatonic reactions to high potency neuroleptic drugs ArchGenPsychiatry 1977 34 947 950
6. White DAC Robins AH Catatonia: harbinger of the neuroleptic malignant syndrome BrJPsychiatry 1991 158 419 421
7. Fink M Is catatonia a primary indication for ECT? ConvulsTher 1990 6 1 4
8. Takahashi S Gjessing LR Studies of periodic catatonia. IV. Longitudinal study of catecholamine metabolism, with and without drugs JPsychiatrRes 1972 9 293 314
9. Fricchione GL Neuroleptic catatonia and its relationship to psychogenic catatonia BiolPsychiatry 1985 20 304 313
10. Mann SC Caroff SN Bleier HR Welz WK Kling MA Hayashida M Lethal catatonia AmJPsychiatry 1986 143 1374 1381
11. Blumer D Catatonia and the neuroleptics: psychobiologic significance of remote and recent findings ComprPsychiatry 1997 38 193 201
12. Hawkins JM Archer KJ Strakowski SM Keck PE Somatic treatment of catatonia IntJPsychiatry Med 1995 25 345 369
13. Philbrick KL Rummans TA Malignant catatonia JNeuropsychiatry ClinNeurosci 1994 6 1 13
14. Valevski A Loebl T Keren T Bodinger L Weizman A Response of catatonia to risperidone: two case reports ClinNeuropharmacol 2001 24 228 231
15. Numata S Kato O Misawa H Kanai T Kasahara T Ohmori T Treatment of catatonia with olanzapine German JPsychiatry 2002 5 115 116
16. Rommel O Tegenthoff M Widdig W Braunig P Malin JP Organic catatonia following frontal lobe injury: response to clozapine JNeuropsychiatry ClinNeurosci 1998 10 237 238
17. Bush G Fink M Petrides G Dowling F Francis A Catatonia. II. Treatment with lorazepam and electroconvulsive therapy Acta PsychiatrScand 1996 93 137 143
18. Rosebush PI Hildebrand AM Furlong BG Mazurek MF Catatonic syndrome in a general psychiatric inpatient population: frequency, clinical presentation, and response to lorazepam JClinPsychiatry 1990 51 357 362
19. Ungvari GS Leung CM Wong MK Lau J Benzodiazepines in the treatment of catatonic syndrome Acta PsychiatrScand 1994 89 285 288
20. Yassa R Iskandar H Lalinec M Cleto L Lorazepam as an adjunct in the treatment of catatonic states: an open clinical trial JClinPsychopharmacol 1990 10 66 68
21. Schmider J Standhart H Deuschle M Drancoli J Heuser I A double-blind comparison of lorazepam and oxazepam in psychomotor retardation and mutism BiolPsychiatry 1999 46 437 441
22. Huang TL Lorazepam and diazepam rapidly relieve catatonic signs in patients with schizophrenia Psychiatry ClinNeurosci 2005 59 52 55
23. Carroll BT The universal field hypothesis of catatonia and neuroleptic malignant syndrome CNS Spectr 2000 5 26 33
24. Yeh AW Lee JW Cheng TC Wen JK Chen WH Clozapine withdrawal catatonia associated with cholinergic and serotonergic rebound hyperactivity: a case report ClinNeuropharmacol 2004 27 216 218